Category Archives: Prescribing Newsletter

Valproate – NICE guidance summary

NICE have published a summary of guidance and safety advice on use of valproate in children, young people and adults – including updated recommendations on prescribing for women or girls with childbearing potential: Do not prescribe valproate for any condition, unless there is no other effective or tolerated treatment available, and only if the terms of the pregnancy Continue Reading »

TARGET Antibiotic Toolkit – Refreshed Patient Leaflets

The RCGP TARGET [Treat Antibiotics Responsibly, Guidance, Education & Tools ] Antibiotic Toolkit has been refreshed and updated in recent months. The updated toolkit now includes a comprehensive guide to the available resources with advice and tips on using them in practice. Among the refreshed resources are: new versions of the Treating Your Infection – Respiratory Tract Infection Continue Reading »

Unlicensed Medicines for Children – Use Standard Strengths

The Neonatal and Paediatric Pharmacists’ Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) have issued a joint statement on using standardised strengths of unlicensed liquid medicines in children. The two bodies strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH- and NPPG- recommended strength, where one exists. There are currently 17 Continue Reading »

NICE Key Therapeutic Topics – 2019 Update

NICE have updated and revised several Key Therapeutic Topic (KTT) documents and added two new topics to the KTT collection of evidence summaries to support medicines optimisation: KTT5 Asthma: medicines safety priorities UPDATE KTT6 Hypnotics UPDATE KTT7 Antipsychotics in people living with dementia UPDATE KTT9 Antimicrobial stewardship- prescribing antibiotics UPDATE KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Continue Reading »

Fluoroquinolone antibiotics – Safety Concerns

Fluoroquinolone antibiotics, such as ciprofloxacin, have a limited place in NICE & Public Health England guidance on managing common infections. Fluoroquinolones may be first line options for treatment of acute prostatitis, epidydimitis,  gonorrhoea & acute pyelonephritis, and second choice options for LRTI, catheter associated LUTI and pelvic inflammatory disease – depending on bacterial susceptibilities and taking account of Continue Reading »